OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Table. 1.

Table. 1.

Positive and negative percent agreement of 12 SARS-CoV-2 antibody assays

Days from symptom onset CLIA EIA LFIA sVNT




Abbott Siemens Roche Euroimmun Vircell BioRad Boditech SD biosensor PCL Sugentech Rapigen GenScript












IgG (%) Total (%) Total (%) IgA (%) IgG (%) IgM+IgA (%) IgG (%) Total (%) IgM (%) IgG (%) IgM (%) IgG (%) IgM (%) IgG (%) IgM (%) IgG (%) IgM (%) IgG (%) IgG (%)
PPA < 8* 40.0 24.0 40.0 21.1 15.8 47.4 42.1 47.4 40.0 32.0 44.0 40.0 40.0 24.0 56.0 32.0 36.0 36.0 40.0
8–14 71.4 63.3 75.5 82.5 55.0 72.5 77.5 90.0 73.5 75.5 83.7 69.4 83.7 71.4 91.8 73.5 87.8 75.5 85.7
> 14 92.3 87.7 89.2 90.0 90.0 94.0 84.0 92.0 86.2 96.9 96.9 92.3 92.3 93.8 98.5 90.8 93.8 89.2 98.5
NPA NA§ 100.0 100.0 100.0 94.9 100.0 97.4 100.0 99.5 98.5 99.0 99.0 100.0 99.0 98.5 96.4 100.0 99.0 97.9 NT

*Includes 25 samples from 22 patients for CLIAs, sVNTs, and LFIAs; 19 samples from 16 patients for EIAs. Includes 49 samples from 34 patients for CLIAs, sVNTs, and LFIAs; 40 samples from 25 patients for EIAs. Includes 65 samples from 25 patients for CLIAs, sVNTs, and LFIAs; 50 samples from 18 patients for EIAs. §N patients=195.

Abbreviations: PPA, positive percent agreement; NPA, negative percent agreement; CLIA, chemiluminescence immunoassay; EIA, enzyme immunoassay; LFIA, lateral flow immunoassay; sVNT, surrogate virus neutralization test; NA, not applicable; NT, not tested.

Ann Lab Med 2021;41:577~587 https://doi.org/10.3343/alm.2021.41.6.577

© Ann Lab Med